Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433440 | 0.89 | CXCR3 (0.71) | CXCR3CYP3A4 | |
| SCHEMBL29411739 | 0.85 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL22965110 | 0.85 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL15064525 | 0.85 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL7021043 | 0.84 | CXCR3 (0.62) | CXCR3CYP3A4 | |
| SCHEMBL16209820 | 0.82 | CXCR3 (0.73) | CXCR3CYP3A4 | |
| SCHEMBL3103736 | 0.81 | CXCR3 (0.60) | CXCR3CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL7020020 | 0.76 | CXCR3 (0.53) | CXCR3 | |
| SCHEMBL4812922 | 0.76 | CXCR3 (0.84) | CXCR3 | |
| SCHEMBL4812909 | 0.76 | CXCR3 (0.84) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20180022810-A1 | USE OF CXCR3 INHIBITORS FOR PROTECTING AGAINST FETAL WASTAGE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| US-20160281165-A1 | METHODS FOR DIAGNOSING, SCREENING, IDENTIFYING, MONITORING, AND TREATING ADVERSE LOCAL TISSUE REACTIONS, WHICH LEAD TO FAILURE OF ORTHOPEDIC IMPLANTS | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | CXCR3, MTOR, CX3CR1 | CXCR3 1/4885CYP3A4 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.